(Q30624174)

English

Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints

scientific article

Statements

Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints (English)
1 reference
0 references
1 reference
1 September 2020
0 references
Emil D Kakkis
1 reference
Mary O'Donovan
1 reference
Gerald Cox
1 reference
Mark Hayes
1 reference
Federico Goodsaid
1 reference
P K Tandon
1 reference
Pat Furlong
1 reference
Susan Boynton
1 reference
Mladen Bozic
1 reference
May Orfali
1 reference
Mark Thornton
1 reference
10
1 reference

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit